NF-kappa B modulation is involved in celastrol induced human multiple myeloma cell apoptosis

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Ni, Haiwen ^a   Zhao, Wanzhou ^b   Kong, Xiangtu ^a   Li, Haitao ^c   Ouyang, Jian ^d  

^a AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b Sino EU Biomedical Innovation Center (SEBIC)   (China)

^c NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^d MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CELASTROL; HEME OXYGENASE 1; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P27; PROTOPORPHYRIN; SURVIVIN; TRANSCRIPTION FACTOR RELA; ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; I KAPPA B; NF-KAPPAB INHIBITOR ALPHA; RELA PROTEIN, HUMAN; TRIPTERINE; TRITERPENE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IC 50; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; STAINING; STRUCTURE ANALYSIS; UPREGULATION; ACTIVE TRANSPORT; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; G1 PHASE CELL CYCLE CHECKPOINT; IC50; METABOLISM; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG SCREENING ASSAYS, ANTITUMOR; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; I-KAPPA B PROTEINS; INHIBITORY CONCENTRATION 50; MULTIPLE MYELOMA; TRANSCRIPTION FACTOR RELA; TRITERPENES;

EID: 84899694806     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095846     Document Type: Article

References (50)

1. Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, et al. (2008) Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 8: 1053-1072.
2. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, et al. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943-2950.
3. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, et al. (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132: 584-593. (Pubitemid 43381591)
4. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC (2009) Multiple myeloma. Lancet 374: 324-339.
5. Kumar S, Rajkumar SV (2006) Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 42: 1612-1622. (Pubitemid 44118763)
6. Kyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 111: 2962-2972.
7. Gupta SC, Kim JH, Prasad S, Aggarwal BB (2010) Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29: 405-434.
8. Bharti AC, Donato N, Singh S, Aggarwal BB (2003) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101: 1053-1062. (Pubitemid 36139379)
9. Zhao W, Entschladen F, Liu H, Niggemann B, Fang Q, et al. (2003) Boswellic acid acetate induces differentiation and apoptosis in highly metastatic melanoma and fibrosarcoma cells. Cancer Detect Prev 27: 67-75. (Pubitemid 36339419)
10. Liu JJ, Nilsson A, Oredsson S, Badmaev V, Zhao WZ, Duan RD (2002) Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcinogenesis 23: 2087-2093. (Pubitemid 36104960)
11. Aggarwal BB, Vijayalekshmi RV, Sung B (2009) Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15: 425-430.
12. Feinman R, Siegel DS, Berenson J (2004) Regulation of NF-kB in multiple myeloma: therapeutic implications. Clin Adv Hematol Oncol 2: 162-166.
13. Karin M (2009) NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 1: a000141.
14. Kannaiyan R, Shanmugam MK, Sethi G (2011) Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett 303: 9-20.
15. Wong KF, Yuan Y, Luk JM (2012) Tripterygium wilfordii bioactive compounds as anticancer and anti-inflammatory agents. Clin Exp Pharmacol Physiol 39: 311-320.
16. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C (2001) Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 25: 1341-1357. (Pubitemid 33022713)
17. Morita T (2010) Celastrol: a new therapeutic potential of traditional Chinese medicine. Am J Hypertens 23: 821.
18. Salminen A, Lehtonen M, Paimela T, Kaarniranta K (2010) Celastrol: Molecular targets of Thunder God Vine. Biochem Biophys Res Commun 394: 439-442.
19. Huang S, Tang Y, Cai X, Peng X, Liu X, et al. (2012) Celastrol inhibits vasculogenesis by suppressing the VEGF-induced functional activity of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 423: 467-472.
20. Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, et al. (2010) Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 7: 17.
21. Yang HS, Kim JY, Lee JH, Lee BW, Park KH, et al. (2011) Celastrol isolated from Tripterygium regelii induces apoptosis through both caspase-dependent and -independent pathways in human breast cancer cells. Food Chem Toxicol 49: 527-532.
22. Yadav VR, Sung B, Prasad S, Kannappan R, Cho SG, et al. (2010) Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. J Mol Med (Berl) 88: 1243-1253.
23. Dai Y, Desano J, Tang W, Meng X, Meng Y, et al. (2010) Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PLoS One 5: e14153.
24. Yang H, Chen D, Cui QC, Yuan X, Dou QP (2006) Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66: 4758-4765.
25. He D, Xu Q, Yan M, Zhang P, Zhou X, et al. (2009) The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer 9: 343.
26. Huang Y, Zhou Y, Fan Y, Zhou D (2008) Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett 264: 101-106.
27. Chen M, Rose AE, Doudican N, Osman I, Orlow SJ (2009) Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Mol Cancer Res 7: 1946-1953.
28. Nagase M, Oto J, Sugiyama S, Yube K, Takaishi Y, Sakato N (2003) Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem 67: 1883-1887. (Pubitemid 39251707)
29. Yamai H, Sawada N, Yoshida T, Seike J, Takizawa H, et al. (2009) Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. Int J Cancer 125: 952-960.
30. Li F, Rajendran P, Sethi G (2010) Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway. Br J Pharmacol 161: 541-554.
31. Berda-Haddad Y, Robert S, Salers P, Zekraoui L, Farnarier C, et al. (2011) Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1alpha. Proc Natl Acad Sci U S A 108: 20684-20689.
32. Zorn JA, Wolan DW, Agard NJ, Wells JA (2012) Fibrils colocalize caspase-3 with procaspase-3 to foster maturation. J Biol Chem 287: 33781-33795.
33. Zorn JA, Wolan DW, Agard NJ, Wells JA (2012) Fibrils colocalize caspase-3 with procaspase-3 to foster maturation. J Biol Chem 287: 33781-33795.
34. Hubackova S, Krejcikova K, Bartek J, Hodny Z (2012) Interleukin 6 signaling regulates promyelocytic leukemia protein gene expression in human normal and cancer cells. J Biol Chem 287: 26702-26714.
35. Nishikori M (2005) Classical and Alternative NF-kB Activation Pathways and Their Roles in Lymphoid Malignancies. Journal of Clinical and Experimental Hematopathology 45:15-24.
36. Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, et al. (2001) Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 115: 279-286. (Pubitemid 34203489)
37. Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309. (Pubitemid 40488635)
38. Alessandrini A, Chiaur DS, Pagano M (1997) Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 11: 342-345. (Pubitemid 27120981)
39. Dai Y, Lawrence TS, Xu L (2009) Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am J Transl Res 1: 1-15.
40. Sethi G, Tergaonkar V (2009) Potential pharmacological control of the NF-kappaB pathway. Trends Pharmacol Sci 30: 313-321.
41. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, et al. (2005) Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42: 588-597. (Pubitemid 41233651)
42. Shah JJ, Orlowski RZ (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23: 1964-1979.
43. Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349-360.
44. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, et al. (2002) The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 115: 141-151. (Pubitemid 34105537)
45. Li F, Sethi G (2010) Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 1805: 167-180.
46. Catz SD, Johnson JL (2001) Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20: 7342-7351. (Pubitemid 33078205)
47. Arumugam TV, Cheng YL, Choi Y, Choi YH, Yang S, et al. (2011) Evidence that gamma-secretase-mediated Notch signaling induces neuronal cell death via the nuclear factor-kappaB-Bcl-2-interacting mediator of cell death pathway in ischemic stroke. Mol Pharmacol 80: 23-31.
48. Rushworth SA, MacEwan DJ (2008) HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood 111: 3793-3801.
49. Alam J, Stewart D, Touchard C, Boinapally S, Choi AM, Cook JL (1999) Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem 274: 26071-26078.
50. Barrera LN, Rushworth SA, Bowles KM, MacEwan DJ (2012) Bortezomib induces heme oxygenase-1 expression in multiple myeloma. Cell Cycle 11: 2248-2252.